JP2004509079A - 効力が増大した修飾生体ペプチド - Google Patents

効力が増大した修飾生体ペプチド Download PDF

Info

Publication number
JP2004509079A
JP2004509079A JP2002515924A JP2002515924A JP2004509079A JP 2004509079 A JP2004509079 A JP 2004509079A JP 2002515924 A JP2002515924 A JP 2002515924A JP 2002515924 A JP2002515924 A JP 2002515924A JP 2004509079 A JP2004509079 A JP 2004509079A
Authority
JP
Japan
Prior art keywords
xaa
peptide
peptide sequence
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002515924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509079A5 (enExample
Inventor
グラベル　デニス
ハビ　アブデルクリム
アブリバット　ティエリー
Original Assignee
セラテクノロジーズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラテクノロジーズ・インコーポレーテッド filed Critical セラテクノロジーズ・インコーポレーテッド
Publication of JP2004509079A publication Critical patent/JP2004509079A/ja
Publication of JP2004509079A5 publication Critical patent/JP2004509079A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/675—Beta-endorphins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002515924A 2000-08-02 2001-08-02 効力が増大した修飾生体ペプチド Pending JP2004509079A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22261900P 2000-08-02 2000-08-02
PCT/CA2001/001119 WO2002010195A2 (en) 2000-08-02 2001-08-02 Modified peptides with increased potency

Publications (2)

Publication Number Publication Date
JP2004509079A true JP2004509079A (ja) 2004-03-25
JP2004509079A5 JP2004509079A5 (enExample) 2005-08-18

Family

ID=22832986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002515924A Pending JP2004509079A (ja) 2000-08-02 2001-08-02 効力が増大した修飾生体ペプチド

Country Status (8)

Country Link
US (1) US20030204063A1 (enExample)
EP (1) EP1305338A2 (enExample)
JP (1) JP2004509079A (enExample)
CN (1) CN1454214A (enExample)
AU (1) AU2001279526A1 (enExample)
BR (1) BR0113178A (enExample)
CA (1) CA2417100A1 (enExample)
WO (1) WO2002010195A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508410A (ja) * 2000-09-18 2004-03-18 オステオミーター・ビオテク・エー／エス Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
JP2011508728A (ja) * 2007-12-21 2011-03-17 ビーエーエスエフ ソシエタス・ヨーロピア ペプチドを含有するフケ防止組成物

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
AU2002228608A1 (en) * 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
GB0205693D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20060110359A1 (en) * 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
EP1543030A2 (en) 2002-09-25 2005-06-22 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
US8603969B2 (en) * 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2006045796A2 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (gip) antigen arrays and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
EP1863537A2 (en) * 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
EP1782819A1 (en) * 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
US8338368B2 (en) * 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2051585A4 (en) * 2006-04-28 2010-06-02 Univ South Florida MATERIALS AND METHODS OF SUPPRESSING INFLAMMATION THROUGH INHIBITION OF THE VORHOF RECEPTOR FOR NATRIURETIC PEPTIDES
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008033518A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
AU2006350707A1 (en) * 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
WO2008086086A2 (en) * 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
JP5114557B2 (ja) * 2007-05-29 2013-01-09 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 危篤状態の患者の転帰を予測する方法
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
WO2010028676A1 (en) * 2008-09-09 2010-03-18 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
PL2427475T3 (pl) * 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
CN102666579A (zh) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2560675A1 (en) * 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
KR20130099938A (ko) 2010-08-13 2013-09-06 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
CA2821766A1 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
BR112013032717A2 (pt) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
EA031230B1 (ru) 2011-06-22 2018-12-28 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты глюкагонового рецептора/glp-1-рецептора
CN104039342A (zh) 2011-10-18 2014-09-10 爱勒让治疗公司 拟肽大环化合物
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
AU2014257131B9 (en) 2013-04-23 2019-12-05 Nizyme, Inc. Methods and compositions for treating diseases
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
MX2017003797A (es) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2016343775B2 (en) * 2015-10-28 2021-07-29 Tufts Medical Center Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
CN109180800B (zh) * 2018-08-01 2019-07-12 广东药科大学 新型生长激素释放激素类似肽二聚体及其应用
US20220241377A1 (en) * 2019-07-24 2022-08-04 Molgenie GmbH Receptor-targeting peptide-drug conjugates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369179A (en) * 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
HUT42101A (en) * 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
US6020311A (en) * 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
KR100543190B1 (ko) * 1995-05-26 2006-06-23 떼라떼끄놀로지 인코퍼레이티드 향상된생물학적효능을갖는키메라성지방체-프로-지알에프유사체
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
IT1283134B1 (it) * 1996-07-08 1998-04-07 Dox Al Italia Spa Derivati sintetici e semisintetici di somatostatine utili nella stimolazione della crescita corporea, in particolare in
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2002506792A (ja) * 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
CN1495198A (zh) * 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
PL205713B1 (pl) * 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004508410A (ja) * 2000-09-18 2004-03-18 オステオミーター・ビオテク・エー／エス Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
JP2004524268A (ja) * 2000-09-18 2004-08-12 オステオミーター・ビオテク・エー／エス 骨関連疾患及び栄養関連疾患の治療、予防、診断及び予後のためにｇｌｐを使用する方法
JP2011508728A (ja) * 2007-12-21 2011-03-17 ビーエーエスエフ ソシエタス・ヨーロピア ペプチドを含有するフケ防止組成物

Also Published As

Publication number Publication date
EP1305338A2 (en) 2003-05-02
US20030204063A1 (en) 2003-10-30
CA2417100A1 (en) 2002-02-07
AU2001279526A1 (en) 2002-02-13
WO2002010195A2 (en) 2002-02-07
BR0113178A (pt) 2004-04-06
CN1454214A (zh) 2003-11-05
WO2002010195A3 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
JP2004509079A (ja) 効力が増大した修飾生体ペプチド
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
US6620910B1 (en) Peptide compounds analogues of the glucagon-like peptide-1 (7-37)
JP4148994B2 (ja) グルカゴン様ペプチド―２アナログ
US5789379A (en) Glucagon-like peptide-2 analogs
RU2128663C1 (ru) Производные полипептида, обладающие инсулинотропной активностью, фармацевтическая композиция, способы усиления действия инсулина, способы лечения диабета
JP2882679B2 (ja) 線状ソマトスタチン類似体
JP4026854B2 (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
CN106414488A (zh) 衍生自毒蜥外泌肽‑4的肽类双重glp‑1/胰高血糖素受体激动剂
JP2011530508A (ja) グルコース依存性インスリン分泌刺激ポリペプチドのアナログ
JP2011530507A (ja) グルコース依存性インスリン分泌刺激ポリペプチドアナログ
JP6113144B2 (ja) 成長ホルモン放出因子（ｇｒｆ）類似体およびその使用
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
EP4638481A1 (en) Glp1/gip/npy2 receptor triple agonists
JPH0769919A (ja) Ｖｉｐ，その類縁体またはそのフラグメントを含む医薬組成物
US11807672B2 (en) Conjugates of islet neogenesis peptides and analogs, and methods thereof
EP2807182A1 (en) Stabilized peptide helices for inhibiting dimerization of chemokine c motif receptor 2 (ccr2)
Stropova et al. H. Bartosz-Bechowski P. Davis J. Slaninova E. Malatynska
HK1033324B (en) Glucagon-like peptide-2 analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031212